ONCOLOGY INSTITUTE INC/THE (TOI) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:TOI • US68236X1000

2.62 USD
-0.06 (-2.24%)
At close: Feb 11, 2026
2.6707 USD
+0.05 (+1.94%)
After Hours: 2/11/2026, 8:00:01 PM

TOI Key Statistics, Chart & Performance

Key Statistics
Market Cap257.76M
Revenue(TTM)461.04M
Net Income(TTM)-54.66M
Shares98.38M
Float89.19M
52 Week High4.88
52 Week Low0.6
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.64
PEN/A
Fwd PEN/A
Earnings (Next)03-05
IPO2020-03-13
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Facilities
TOI short term performance overview.The bars show the price performance of TOI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

TOI long term performance overview.The bars show the price performance of TOI in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of TOI is 2.62 USD. In the past month the price decreased by -25.78%. In the past year, price increased by 172.6%.

ONCOLOGY INSTITUTE INC/THE / TOI Daily stock chart

TOI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to TOI. When comparing the yearly performance of all stocks, TOI is one of the better performing stocks in the market, outperforming 94.75% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
TOI Full Technical Analysis Report

TOI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TOI. TOI has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TOI Full Fundamental Analysis Report

TOI Financial Highlights

Over the last trailing twelve months TOI reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 16.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -33.41%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%22.22%
Sales Q2Q%36.7%
EPS 1Y (TTM)16.56%
Revenue 1Y (TTM)21.67%
TOI financials

TOI Forecast & Estimates

8 analysts have analysed TOI and the average price target is 6.63 USD. This implies a price increase of 153.05% is expected in the next year compared to the current price of 2.62.

For the next year, analysts expect an EPS growth of -36.9% and a revenue growth 20.72% for TOI


Analysts
Analysts82.5
Price Target6.63 (153.05%)
EPS Next Y-36.9%
Revenue Next Year20.72%
TOI Analyst EstimatesTOI Analyst Ratings

TOI Ownership

Ownership
Inst Owners40.02%
Ins Owners3.63%
Short Float %7.79%
Short Ratio3.39
TOI Ownership

TOI Competitors/Peers

The largest stocks on the US markets in the "Health Care Facilities" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
HCA HCA HEALTHCARE INC17.53114.563B
THC TENET HEALTHCARE CORP13.6316.966B
UHS UNIVERSAL HEALTH SERVICES-B9.7413.294B
ENSG ENSIGN GROUP INC/THE28.6711.85B
EHC ENCOMPASS HEALTH CORP19.3310.968B
PACS PACS GROUP INC18.946.182B
BKD BROOKDALE SENIOR LIVING INC N/A3.871B
CON CONCENTRA GROUP HOLDINGS PAR16.163.058B
NHC NATIONAL HEALTHCARE CORP N/A2.524B
SEM SELECT MEDICAL HOLDINGS CORP12.261.969B

About TOI

Company Profile

TOI logo image The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California and currently employs 825 full-time employees. The company went IPO on 2020-03-13. The firm manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The firm's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The firm also provides management services to over 14 clinic locations owned by independent oncology practices. The firm and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Company Info

ONCOLOGY INSTITUTE INC/THE

18000 Studebaker Rd, Suite 800

Cerritos CALIFORNIA US

CEO: Steven Hochberg

Employees: 825

TOI Company Website

TOI Investor Relations

Phone: 15627353226

ONCOLOGY INSTITUTE INC/THE / TOI FAQ

Can you describe the business of ONCOLOGY INSTITUTE INC/THE?

The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California and currently employs 825 full-time employees. The company went IPO on 2020-03-13. The firm manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The firm's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The firm also provides management services to over 14 clinic locations owned by independent oncology practices. The firm and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.


Can you provide the latest stock price for ONCOLOGY INSTITUTE INC/THE?

The current stock price of TOI is 2.62 USD. The price decreased by -2.24% in the last trading session.


Does ONCOLOGY INSTITUTE INC/THE pay dividends?

TOI does not pay a dividend.


What is the ChartMill technical and fundamental rating of TOI stock?

TOI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy TOI stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TOI.


What is the expected growth for TOI stock?

The Revenue of ONCOLOGY INSTITUTE INC/THE (TOI) is expected to grow by 20.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for ONCOLOGY INSTITUTE INC/THE?

ONCOLOGY INSTITUTE INC/THE (TOI) currently has 825 employees.